Home » Stocks » Therapix Biosciences

Therapix Biosciences Ltd. (TRPX)

Jul 2, 2020 - Stock symbol was changed to TRPXY (reason: delisted from NASDAQ)
Stock Price: $0.320 USD 0.000 (0.00%)
Updated Jul 1, 2020 4:00 PM EDT

Stock Price Chart

Key Info

Market Cap 1.83M
Revenue (ttm) n/a
Net Income (ttm) -4.58M
Shares Out 5.72M
EPS (ttm) -1.28
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day Jul 1, 2020
Last Price $0.320
Previous Close $0.320
Change ($) 0.000
Change (%) 0.00%
Day's Open -
Day's Range 0.301 - 0.400
Day's Volume 0
52-Week Range 0.250 - 4.690

More Stats

Market Cap 1.83M
Enterprise Value 1.11M
Earnings Date (est) n/a
Ex-Dividend Date n/a
Shares Outstanding 5.72M
Float n/a
EPS (basic) 0.64
EPS (diluted) -1.28
FCF / Share -0.39
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 187,878
Short Ratio 0.05
Short % of Float n/a
Beta 0.39
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio n/a
PB Ratio 734.59
Revenue n/a
Operating Income -4.11M
Net Income -4.58M
Free Cash Flow -3.97M
Net Cash 719,000
Net Cash / Share 0.13
Gross Margin n/a
Operating Margin n/a
Profit Margin n/a
FCF Margin n/a
ROA -89.87%
ROE -9,843.96%
ROIC 685.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Summary

Analyst Ratings (0)

Buy 0
Overweight 0
Hold 0
Underweight 0
Sell 0

Analyst Consensus: n/a

Price Target

$18.00*
Low
18.0
Current: $0.320
High
18.0
Target: 18.00
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014
Revenue------
Operating Income-4.11-7.24-5.75-2.01-1.60-7.04
Net Income-4.58-9.38-6.241.992.54-7.21
Shares Outstanding20414041.0041.00--
Earnings Per Share0.641.201.00-1.00-2.20-9.00
EPS Growth-46.67%20%----
Operating Cash Flow-4.70-7.13-4.58-1.47-1.40-7.36
Capital Expenditures0.720.03-0.04--0.22
Free Cash Flow-3.97-7.11-4.62-1.48-1.40-7.14
Cash & Equivalents0.882.039.220.696.180.66
Total Debt0.160.87----
Net Cash / Debt0.721.169.220.696.180.66
Assets1.154.569.571.256.501.02
Liabilities1.144.481.180.671.991.47
Book Value0.010.198.390.575.11-0.14
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Therapix Biosciences Ltd.
Country Israel
CEO Gilad Bar-Lev

Stock Information

Ticker Symbol TRPX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: TRPX
IPO Date March 22, 2017

Description

Therapix Biosciences, a specialty clinical-stage pharmaceutical company, develops drugs based on cannabinoid molecules. Its drug development programs include THX-110, which has completed Phase II a clinical trial for the treatment of Tourette syndrome and Obstructive Sleep Apnea; THX-160, which has completed two preliminary preclinical studies for the treatment of acute and chronic pain; and THX-210 for the treatment of autism spectrum disorder and epilepsy. The company was formerly known as NasVax Ltd. and changed its name to Therapix Biosciences Ltd. in November 2013. Therapix Biosciences Ltd. was founded in 2004 and is headquartered in Givatayim, Israel.